Literature DB >> 74379

Plasma kallikrein activation and inhibition during typhoid fever.

R W Colman, R Edelman, C F Scott, R H Gilman.   

Abstract

As an ancillary part of a typhoid fever vaccine study, 10 healthy adult male volunteers (nonimmunized controls) were serially bled 6 days before to 30 days after ingesting 10(5)Salmonella typhi organisms. Five persons developed typhoid fever 6-10 days after challenge, while five remained well. During the febrile illness, significant changes (P < 0.05) in the following hematological parameters were measured: a rise in alpha(1)-antitrypsin antigen concentration and high molecular weight kininogen clotting activity; a progressive decrease of platelet count (to 60% of the predisease state), functional prekallikrein (55%) and kallikrein inhibitor (47%) with a nadir reached on day 5 of the fever and a subsequent overshoot during convalescence. Despite the drop in functional prekallikrein and kallikrein inhibitor, there was no change in factor XII clotting activity or antigenic concentrations of prekallikrein and the kallikrein inhibitors, C1 esterase inhibitor (C1-INH) and alpha(2)-macroglobulin. Plasma from febrile patients subjected to immunoelectrophoresis and crossed immunoelectrophoresis contained a new complex displaying antigenic characteristics of both prekallikrein and C1-INH; the alpha(2)-macroglobulin, antithrombin III, and alpha(1)-antitrypsin immunoprecipitates were unchanged. Plasma drawn from infected-well subjects showed no significant change in these components of the kinin generating system. The finding of a reduction in functional prekallikrein and kallikrein inhibitor (C1-INH) and the formation of a kallikrein C1-INH complex is consistent with prekallikrein activation in typhoid fever. The correlation of these changes with the drop in platelet count suggests that a common mechanism may be responsible.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 74379      PMCID: PMC372538          DOI: 10.1172/jci108938

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Activation of plasma by contact with glass: evidence for a common reaction which releases plasma kinin and initiates coagulation.

Authors:  J MARGOLIS
Journal:  J Physiol       Date:  1958-11-10       Impact factor: 5.182

2.  [A micro-method of immuno-electrophoresis].

Authors:  J J SCHEIDEGGER
Journal:  Int Arch Allergy Appl Immunol       Date:  1955

3.  The role of Hageman factor in disseminated intravascular coagulation induced by septicemia, neoplasia, or liver disease.

Authors:  J W Mason; R W Colman
Journal:  Thromb Diath Haemorrh       Date:  1971-10-31

4.  Interaction of plasma kallikrein with the C1 inhibitor.

Authors:  I Gigli; J W Mason; R W Colman; K F Austen
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

5.  A pre-albumin activator of prekallikrein.

Authors:  A P Kaplan; K F Austen
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

6.  Plasma kallikrein and Hageman factor in Gram-negative bacteremia.

Authors:  J W Mason; U Kleeberg; P Dolan; R W Colman
Journal:  Ann Intern Med       Date:  1970-10       Impact factor: 25.391

7.  Typhoid fever with consumption coagulopathy.

Authors:  N Allen; Y Nomanbhoy; D Green; G Dunea
Journal:  JAMA       Date:  1969-04-28       Impact factor: 56.272

8.  Platelet counts with the Coulter counter.

Authors:  B S Bull; M A Schneiderman; G Brecher
Journal:  Am J Clin Pathol       Date:  1965-12       Impact factor: 2.493

9.  Study of induced typhoid fever in man. I. Evaluation of vaccine effectiveness.

Authors:  R B Hornick; T E Woodward; F R McCrumb; M J Snyder; A T Dawkins; J T Bulkeley; F De la Macorra; F A Corozza
Journal:  Trans Assoc Am Physicians       Date:  1966

10.  Separation of plasma thromboplastin antecedent from kallikrein by the plasma 2 -macroglobulin, kallikrein inhibitor.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1971-10       Impact factor: 14.808

View more
  15 in total

1.  Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis.

Authors:  A Stadnicki; M Gonciarz; T J Niewiarowski; J Hartleb; M Rudnicki; N B Merrell; R A Dela Cadena; R W Colman
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

2.  Recombinant alpha 1-antitrypsin Pittsburgh attenuates experimental gram-negative septicemia.

Authors:  R W Colman; D N Flores; R A De La Cadena; C F Scott; L Cousens; P J Barr; I B Hoffman; F Kueppers; D Fisher; S Idell
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

3.  Selective plasma kallikrein inhibitor attenuates acute intestinal inflammation in Lewis rat.

Authors:  A Stadnicki; R A DeLa Cadena; R B Sartor; D Bender; C A Kettner; H C Rath; A Adam; R W Colman
Journal:  Dig Dis Sci       Date:  1996-05       Impact factor: 3.199

Review 4.  Surface-mediated defense reactions. The plasma contact activation system.

Authors:  R W Colman
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

5.  Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma.

Authors:  C F Scott; R W Colman
Journal:  J Clin Invest       Date:  1980-02       Impact factor: 14.808

6.  Transcriptional response in the peripheral blood of patients infected with Salmonella enterica serovar Typhi.

Authors:  Lucinda J Thompson; Sarah J Dunstan; Christiane Dolecek; Tim Perkins; Deborah House; Gordon Dougan; Thi Hue Nguyen; Thi Phi La Tran; Cong Du Doan; Thi Phuong Le; Thi Dung Nguyen; Tinh Hien Tran; Jeremy J Farrar; Denise Monack; David J Lynn; Stephen J Popper; Stanley Falkow
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-11       Impact factor: 11.205

7.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 8.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

Review 9.  Human plasma kallikrein-kinin system: physiological and biochemical parameters.

Authors:  J W Bryant; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-07

10.  Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen.

Authors:  C F Scott; M Schapira; H L James; A B Cohen; R W Colman
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.